AVM Biotechnology is a clinical stage company treating a variety of blood cancers and solid tumors with our immunomodulatory AVM0703. In our enrolling adaptive design expansion Phase 2 trial for R/R NHL (NCT04329728), AVM is distinguished from other anti-cancer drugs by few and mild drug-related adverse events, and by survival as a monotherapy or a combination therapy. For information to become a trial site or for information about referring a patient please contact info@avmbiotech.com.